- Conditions
- Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Thyroid Cancer, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
- Interventions
- sorafenib tosylate, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 70 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2353–2376
of 22,541
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumors
- Interventions
- Atezolizumab, RO6958688
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 11
- States / cities
- Santa Monica, California • Stanford, California • Aurora, Colorado + 7 more
- Conditions
- Thyroid Cancer
- Interventions
- 300mg vandetanib, 150mg vandetanib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Menorrhagia
- Interventions
- Oral tranexamic acid, Oral Contraceptive Pills
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 21 Years · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Malignant Skin Tumor, Soft Tissue Tumor, Malignant
- Interventions
- Diffusing Alpha-emitter Radiation Therapy
- Radiation
- Lead sponsor
- Alpha Tau Medical LTD.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Des Moines, Iowa • New York, New York • Germantown, Tennessee + 2 more
- Conditions
- Healthy
- Interventions
- Glimepiride 1mg Tablets
- Drug
- Lead sponsor
- Ranbaxy Laboratories Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Venous Thrombosis
- Interventions
- Shortened duration (6 weeks) of anticoagulant therapy, Conventional duration (3 months) of anticoagulant therapy, No Intervention
- Other
- Lead sponsor
- Johns Hopkins All Children's Hospital
- Other
- Eligibility
- Up to 20 Years
- Enrollment
- 532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2022
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more
- Conditions
- X-linked Hypophosphatemia
- Interventions
- KRN23
- Drug
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 5
- States / cities
- San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
- Conditions
- Smoking Cessation, Smoking
- Interventions
- Standard Treatment (ST), Telephone Counseling, Quitline, Nicotine Replacement Therapy (NRT)
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 639 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
- Interventions
- Lecanemab, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
- Conditions
- Relapsed/Refractory, Multiple Myeloma
- Interventions
- Mezagitamab, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 7
- States / cities
- Duarte, California • St Louis, Missouri • New York, New York + 3 more
- Conditions
- Obesity, Childhood
- Interventions
- ReCHARGE, TAU
- Behavioral
- Lead sponsor
- University of Houston
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 392 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- Sibeprenlimab 400 mg, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
- Conditions
- Esophageal Motility Disorders
- Interventions
- Per-oral Endoscopic Myotomy, Speedboat (Bipolar electrocautery knife)
- Procedure · Device
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Macular Degeneration
- Interventions
- Zifibancimig, Ranibizumab, Port Delivery Platform
- Drug · Device
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 36
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Encino, California + 32 more
- Conditions
- Transthyretin Amyloidosis With Cardiomyopathy
- Interventions
- Nucresiran, Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 2,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 45
- States / cities
- La Jolla, California • Laguna Hills, California • Stanford, California + 38 more
- Conditions
- Cardiovascular Disease and Lipoprotein(a)
- Interventions
- TQJ230, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 8,323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 287
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 136 more
- Conditions
- Prostate Carcinoma
- Interventions
- Multiparametric Magnetic Resonance Imaging
- Diagnostic Test
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 852 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • New Haven, Connecticut + 31 more
- Conditions
- Covid19
- Interventions
- Placebo, Metformin
- Other · Drug
- Lead sponsor
- Susanna Naggie, MD
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 3,214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 110
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
- Conditions
- Sjogrens Syndrome
- Interventions
- Ianalumab (VAY736), Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 612 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 32
- States / cities
- Fullerton, California • La Palma, California • Van Nuys, California + 27 more
- Conditions
- Diabetes Mellitus, Type 2, Heart Failure, Diastolic
- Interventions
- Exenatide
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Migraine Disorders
- Interventions
- ALD403, Placebo
- Biological
- Lead sponsor
- Alder Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 665 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 82
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
- Conditions
- Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Ramucirumab, Capecitabine, Cisplatin, Placebo, Fluorouracil
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 645 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 25
- States / cities
- Fayetteville, Arkansas • Bakersfield, California • Fullerton, California + 19 more
- Conditions
- HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias, Early Stage Lower Genital Tract Cancers
- Interventions
- Diagnostic tests for anal cancer screening
- Diagnostic Test
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- New York, New York • Charleston, South Carolina • Houston, Texas